NGS of the tumor biopsies from the initial diagnosis and from the relapse from March 2022 revealed that the tumor was IDH1 and IDH2 wild type and harbored an FGFR3-TACC3 fusion (Figure 1, Supplementary Table S1). The gene discussed is IDH1; the disease is neoplasm.